ORMP
Oramed Pharmaceuticals Inc.
There isn't enough reported data to score ORMP yet.
UNH
UnitedHealth Group Incorporated
UNH's fundamentals are mixed: free cash flow grew 31%, but earnings per share fell 8.5%. At 23x earnings, it's trading right at its usual valuation. Analysts expect strong earnings growth, though they disagree widely on how much.
ORMP Fundamentals
| Metric | Status |
|---|---|
| Unavailable | |
| Strong | |
| Unavailable | |
| Unavailable |
ORMP's profitability is currently strong. There isn't enough data to rate its revenue, cash flow and balance sheet.
UNH Fundamentals
| Metric | Status |
|---|---|
| Stable | |
| Stable | |
| Healthy | |
| Healthy |
UNH's cash flow and balance sheet are currently healthy, and its revenue and profitability are stable.
ORMP PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Current | 1.2x | $4.03 | — |
| Cheap | 1.5x | $5.25 | +30% |
| Fair | 5.7x | $19.40 | +381% |
| Expensive | 85x | $290 | +7101% |
Historical ranges are pointers, not guarantees.
ORMP has the edge over UNH in the historical PE scenario, which offers more potential upside but is not a forecast.
UNH PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 18x | $405 | — |
| Cheap | 19x | $325 | -20% |
| Fair | 23x | $410 | +1.2% |
| Current | 23x | $405 | — |
| Expensive | 30x | $526 | +30% |
Historical ranges are pointers, not guarantees.
UNH's PE is in its fair range at 23x. If earnings grow as analysts expect, today's price would be 18x next year's earnings, in its cheap range.
ORMP Forward outlook
There aren't enough analyst estimates for ORMP to show an outlook.
UNH Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Stable | |
| Improving | |
| Moderate | |
| Low |
Analysts expect UNH's earnings to grow and its profitability to improve, with its revenue holding steady. However, they disagree widely on these estimates.
ORMP Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | $3.43 | +246% |
| Q2 2026 | $4.13 | +$4.75 |
| Q1 2026 | $2.60 | +$3.31 |
| Q4 2025 | $1.50 | +$1.98 |
| Q3 2025 | $0.99 | +$1.03 |
| Q2 2025 | -$0.62 | -272% |
| Q1 2025 | -$0.71 | -745% |
| Q4 2024 | -$0.48 | -443% |
ORMP has the edge over UNH on earnings, with more consistent year-over-year improvement.
UNH Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $22.65 | +29% |
| Q3 2026 | $17.55 | -8.5% |
| Q2 2026 | $15.58 | -33% |
| Q1 2026 | $13.28 | -44% |
| Q4 2025 | $13.23 | -15% |
| Q3 2025 | $19.17 | +25% |
| Q2 2025 | $23.09 | +53% |
| Q1 2025 | $23.89 | +46% |
| Q4 2024 | $15.51 | -35% |
UNH's earnings per share have fallen from their peak: $17.55 over the past year, against $23.89 in early 2025.
ORMP Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q2 2023 | $674K | 0% |
| Q1 2023 | $666K | 0% |
| Q4 2022 | $681K | -25% |
| Q3 2022 | $682K | -0.1% |
| Q2 2022 | $674K | -1% |
| Q1 2022 | $666K | +0.2% |
| Q4 2021 | $904K | +34% |
| Q4 2021 | $674K | 0% |
ORMP's revenue is growing: $0 last quarter.
| Quarter | Margin | YoY |
|---|---|---|
| Q1 2025 | -225% | N/A |
| Q2 2023 | -562% | +1132 points |
| Q1 2023 | -782% | +908 points |
| Q4 2022 | -1430% | -67 points |
| Q3 2022 | -1201% | -4.9 points |
| Q2 2022 | -1694% | -609 points |
| Q1 2022 | -1689% | -791 points |
| Q4 2021 | -1364% | -632 points |
ORMP's operating margin was −225% last quarter, up 976 points from the same quarter a year ago, near the top of its range since 2020.
UNH Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $112.7B | -0.4% |
| Q2 2026 | $112B | +0.4% |
| Q1 2026 | $111.7B | +2% |
| Q4 2025 | $113.2B | +12% |
| Q3 2025 | $113.2B | +12% |
| Q2 2025 | $111.6B | +13% |
| Q1 2025 | $109.6B | +9.8% |
| Q4 2024 | $100.8B | +6.8% |
UNH's revenue has held roughly level: $113B last quarter, about level with the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 5.8% | +2 points |
| Q2 2026 | 7.1% | +2.5 points |
| Q1 2026 | 8.1% | -0.3 points |
| Q4 2025 | 0.3% | -7.4 points |
| Q3 2025 | 3.8% | -4.8 points |
| Q2 2025 | 4.6% | -3.4 points |
| Q1 2025 | 8.3% | +0.4 points |
| Q4 2024 | 7.7% | -0.4 points |
UNH's operating margin was 5.8% last quarter, up 2 points from the same quarter a year ago.
ORMP Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $422K | +$2M |
| Q2 2026 | -$202K | +$3.3M |
| Q1 2026 | -$2.9M | +$602K |
| Q4 2025 | -$468K | +$1.5M |
| Q3 2025 | -$1.6M | +$5.5M |
| Q2 2025 | -$3.5M | -270% |
| Q1 2025 | -$3.5M | -$2M |
| Q4 2024 | -$1.9M | -$501K |
ORMP has burned cash in almost every quarter: −$3M over the past year, against −$11M the year before.
UNH Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $4.3B | -16% |
| Q2 2026 | $10.3B | +63% |
| Q1 2026 | $8.1B | +79% |
| Q4 2025 | $160M | -89% |
| Q3 2025 | $5.1B | -61% |
| Q2 2025 | $6.3B | +6.9% |
| Q1 2025 | $4.6B | +1037% |
| Q4 2024 | $1.5B | +$7.6B |
UNH has the edge over ORMP on cash generation, producing positive trailing cash flow while its opponent burns cash.
ORMP Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +1.2% | +514K shares |
| 1 year | +0.6% | +241K shares |
| 3 years | +6.4% | +2.6M shares |
| 5 years | +17% | +6.3M shares |
| Available history | +141% | +25.2M shares |
ORMP has 43M diluted shares, up 0.6% from a year ago.
| Quarter | Spent |
|---|---|
| Q4 2025 | $4M |
| Q3 2025 | $361,000 |
| Q4 2024 | $1.2M |
UNH Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -0.4% | -4M shares |
| 1 year | -0.7% | -6M shares |
| 3 years | -3.6% | -34M shares |
| 5 years | -5.5% | -53M shares |
| Available history | -6.6% | -64M shares |
UNH has the edge over ORMP on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | $3.4B |
| Q2 2026 | $1.6B |
| Q1 2026 | — |
| Q4 2025 | — |
| Q3 2025 | — |
| Q2 2025 | $2.5B |
| Q1 2025 | $3B |
| Q4 2024 | $5B |
UNH spent $5B buying back its own shares over the past year, down 52% from the year before.
ORMP Net Leverage
UNH Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 1.7x | Healthy |
| Q2 2026 | 1.7x | Healthy |
| Q1 2026 | 2.2x | Moderate |
| Q4 2025 | 2.3x | Moderate |
| Q3 2025 | 1.7x | Healthy |
| Q2 2025 | 1.5x | Healthy |
| Q1 2025 | 1.3x | Healthy |
| Q4 2024 | 1.4x | Healthy |
UNH's net debt is about 1.7 years of its operating earnings (EBITDA), about the same as a year ago.
ORMP Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 46.8 | Neutral |
| Stochastic | 8.9 | Oversold |
ORMP's weekly RSI is 47 (neutral) and its Stochastic is 9 (oversold).
UNH Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 56.4 | Neutral |
| Stochastic | 60.0 | Neutral |
UNH's weekly RSI is 56 (neutral) and its Stochastic is 60 (neutral).
ORMP PE vs Healthcare Sector
| Metric | ORMP | Sector median | Relative |
|---|---|---|---|
| PE | 1.2x | 26x | 95% below |
| PE % | 10 | 29 | 19 pts below |
ORMP has the edge over UNH on valuation relative to its sector.
UNH PE vs Healthcare Sector
| Metric | UNH | Sector median | Relative |
|---|---|---|---|
| PE | 23x | 26x | 11% below |
| PE % | 47 | 29 | 18 pts above |
UNH is trading at 23x earnings, a 11% discount to the Healthcare sector's median of 26x.
ORMP Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $4.22 | 4.5% below |
| 20 week MA | $4.38 | 8% below |
| 50 week MA | $3.89 | 3.6% above |
| 100 week MA | $3.08 | 31% above |
| 200 week MA | $2.83 | 42% above |
ORMP has pulled back, but its long-term trend is still up: it's below its 8- and 20-week averages, but 42% above its 200-week average.
UNH Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $394.2 | 2.8% above |
| 20 week MA | $400.5 | 1.2% above |
| 50 week MA | $361.2 | 12% above |
| 100 week MA | $376.0 | 7.8% above |
| 200 week MA | $446.6 | 9.3% below |
UNH has the edge over ORMP on trend strength, trading above more of its moving averages.
ORMP Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $5.18 | $4.54 | -12% |
| 2021 | $4.54 | $15.5 | +242% |
| 2022 | $15.5 | $11.0 | -29% |
| 2023 | $11.0 | $2.31 | -79% |
| 2024 | $2.31 | $2.37 | +2.6% |
| 2025 | $2.37 | $2.95 | +24% |
| 2026 YTD | $2.95 | $4.03 | +37% |
ORMP has the edge over UNH on returns for 2026, with the stronger performance.
UNH Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $296.0 | $340.8 | +15% |
| 2021 | $340.8 | $495.4 | +45% |
| 2022 | $495.4 | $531.3 | +7.3% |
| 2023 | $531.3 | $526.5 | -0.9% |
| 2024 | $526.5 | $510.0 | -3.1% |
| 2025 | $510.0 | $331.8 | -35% |
| 2026 YTD | $331.8 | $405.1 | +22% |
UNH has finished three years in a row lower, and it's up 22% so far in 2026.